ETON - Company ID 0001710340
The table below shows Eton Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $79.95M | $39.01M | $31.64M | $21.25M | $21.83M | $39.00K |
| Cost of revenue | $37.21M | $15.60M | $10.58M | $6.93M | $2.83M | $436.00K |
| Gross profit | $42.74M | $23.41M | $21.06M | $14.32M | $19.00M | -$397.00K |
| R&D | $7.76M | $3.25M | $3.32M | $4.00M | $6.24M | $14.10M |
Eton Pharmaceuticals, Inc. reported annual revenue of $79.95M for fiscal year 2025. That is up 104.9% from $39.01M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $959.00K (FY 2019) to $79.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $35.82M |
| $22.75M |
| $18.93M |
| $18.58M |
| $14.27M |
| $12.61M |
| Operating income | -$844.00K | -$2.60M | -$1.19M | -$8.26M | -$1.50M | -$27.11M |
| Income tax | $43.00K | $15.00K | $247.00K | $0.00 | $0.00 | - |
| Net income | -$4.60M | -$3.82M | -$936.00K | -$9.02M | -$1.96M | -$27.97M |
| EPS (diluted) | - | - | - | - | - | - |